FORAGER-1: A Study of LOXO-435 (LY3866288) in Participants With Cancer With a Change in a Gene Called FGFR3

Launched by ELI LILLY AND COMPANY · Nov 7, 2022

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment called LOXO-435 for patients with certain types of cancer, particularly those affecting the urinary system, like bladder and ureteral cancers. The trial aims to find out how safe LOXO-435 is, what side effects might occur, and how well it works for patients whose cancer has a specific change in a gene called FGFR3. If you or someone you know has advanced or metastatic cancer with this genetic change, you may be eligible to participate in the study.

To join, participants need to have a confirmed FGFR3 gene alteration and a specific type of cancer that can be measured. They should also be in good general health, meaning they can perform daily activities with minimal assistance. Participation in the trial could last up to 30 months or longer if the cancer does not progress. Throughout the study, participants will receive regular check-ups to monitor their health and the effects of the treatment. It's important to note that this trial is currently recruiting patients of all genders aged 65 and older.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Have solid tumor cancer with an FGFR3 pathway alteration on molecular testing in tumor or blood sample that is deemed as actionable
• • Cohort A1: Presence of an alteration in FGFR3 or its ligands
• • Cohort A2, B2, B3, and B5: Histological diagnosis of urothelial cancer (UC) that is locally advanced or metastatic with a qualifying FGFR3 genetic alteration
• • Cohorts B1 and B4: Histological diagnosis of urothelial cancer that is locally advanced or metastatic
• • Cohort C1: Must have histological diagnosis of a non-urothelial solid tumor malignancy that is locally advanced or metastatic with a qualifying FGFR3 genetic alteration
• * Measurability of disease:
• • Cohort A1 and B3: Measurable or non-measurable disease as defined by Response Evaluation Criteria in Solid Tumors v 1.1 (RECIST v1.1)
• • Cohorts A2, B1, B2, B4, B5, and C1: Measurable disease required as defined by RECIST v1.1
• • Have adequate tumor tissue sample available. Participants with inadequate tissue sample availability may still be considered for enrollment upon review
• • Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 for Cohorts A1, A2, B3, and B5
• • Less than or equal to 2 for Cohorts B1, B2, B4, and C1
• * Prior Systemic Therapy Criteria:
• • Cohort A1/C1: Participant has received all standard therapies for which the participant was deemed to be an appropriate candidate by the treating Investigator; OR the participant is refusing the remaining most appropriate standard of care treatment; OR there is no standard therapy available for the disease. There is no restriction on number of prior therapies.
• • Cohort A2, B2, B3 participants must have received at least one prior regimen, and cohorts B1 and B4 participants at least 2 prior regimens, in the locally advanced or metastatic setting
• • There is no restriction on number of prior therapies
• • Cohort B5: Participants have not received prior systemic therapy for locally advanced or metastatic UC
• * FGFR inhibitor specific requirements:
• • Cohort A1/A2/B3: Prior FGFR inhibitor treatment is permitted but not required
• • Cohort B1/B4: Participants must have been previously treated with erdafitinib
• • Cohort B2, B5, and C1: Participants must be FGFR inhibitor naïve
• Exclusion Criteria:
• • Participants with primary central nervous system (CNS) malignancy
• • Untreated or uncontrolled CNS metastases
• • Current evidence of corneal keratopathy or retinal disorder. Individuals with asymptomatic ophthalmic conditions may be eligible
• • Any serious unresolved toxicities from prior therapy
• • Significant cardiovascular disease
• • Prolongation of the QT interval corrected for heart rate using Fridericia's formula (QTcF)
• • Active uncontrolled systemic infection or other clinically significant medical conditions
• • Participants who are pregnant, lactating, or plan to breastfeed during the study or within 6 months of the last dose of study treatment. Participants who have stopped breastfeeding may be enrolled